In 2016, branded biologic sales in oncology, immunology, endocrinology, and nephrology across the major markets exceeded $70 billion. Sales from biosimilars in the same therapy areas and regions totaled approximately $1.5 billion. Throughout our 2016-2026 forecast period, increasing numbers of branded biologics are set to lose patent protection, with biosimilars expected to enter the market and erode both patient share and drug prices. We present our forecasts for key reference brands and their biosimilars by therapeutic area, molecule, and region.